ALEMBIC LTD. - 506235 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0330 Name of the Signatory :- Drigesh MittalDesignation :- Company Secretary and Compliance Officer ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the following share certificate(s) of the Company has been reported as lost/misplaced and the shareholder of such lost share certificate(s) has requested the Company for issue of duplicate share certificate(s): Also find attached herewith copy of email received from RTA as a proof of date of receipt of information by the Company. We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the following registered shareholder(s) and/or legal heir(s) of the registered shareholder(s) on 4th July, 2022: We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the following share certificate(s) of the Company has been reported as lost/misplaced and the shareholder of such lost share certificate(s) has requested the Company for issue of duplicate share certificate(s): Also find attached herewith copy of email received from RTA as a proof of date of receipt of information by the Company. We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Closure of Trading Window
With reference to the captioned matter, this is to inform the exchange that in terms of the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company will remain closed from 1st July, 2022 till 48 hours after the declaration of the unaudited financial results for the quarter ended 30th June, 2022. The date of the Board Meeting for considering the unaudited financial results for the quarter ended 30th June, 2022, will be intimated in due course. We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the following share certificate(s) of the Company has been reported as lost/misplaced and the shareholder of such lost share certificate(s) has requested the Company for issue of duplicate share certificate(s): Also find attached herewith copy of email received from RTA as a proof of date of receipt of information by the Company. We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the following share certificate(s) of the Company has been reported as lost/misplaced and the shareholder of such lost share certificate(s) has requested the Company for issue of duplicate share certificate(s): Also find attached herewith copy of email received from RTA as a proof of date of receipt of information by the Company. We request you to kindly take the same on record.
Alembic gets USFDA nod for cancer treatment drug
The company has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Dasatinib tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, Alembic Pharmaceuticals said in a statement. ALEMBIC LTD. - 506235 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of Listing Regulations, 2015, we enclose herewith a copy of Notice w.r.t. transfer of Equity Shares of the Company to Investor Education and Protection Fund (IEPF) published in English and vernacular language (Gujarati) newspapers on 31st May, 2022 in Indian Express and Financial Express. We request you to please take the same on record. ALEMBIC LTD. - 506235 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations, 2015")
Pursuant to Regulation 30 of the Listing Regulations, 2015, we enclose herewith a specimen of the reminder letter dated 20th May, 2022 sent to the relevant shareholders for whom the dividend remains unpaid / unclaimed for seven or more consecutive years and whose shares are liable to be transferred to the Investor Education and Protection Fund ("IEPF") Authority as per Section 124(6) of the Companies Act, 2013 read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended from time to time. We request you to kindly take the same on record.